Ann: Results of Meeting, page-51

I didn't get to see or watch LC's performance but i dare say this isn't one of the public encounters she or any other members of the board want to be doing, It isn't the most glamorous Cap Raises. To me this has gone against PH's own words - "raise when you can, not when you need to".
Stevie Wonder could see how bad the current sentiment is amongst shareholders, I'm sure IMU have someone monitoring Hotcopper which at current times is 95% negativity.
However i do hold confidence that IMU will return to its 2021 state. We a lot of expected news in the near future and at this stage, everything appears to be going as planned.
It's disappointing about Her-vaxx and the others dropping off, but with the limited funds available they really need to focus on the more recent acquisitions (CF-33 & Azer-cell).
It is noted that the proposed studies Neo-Polem & the combo between PD1-Vaxx & Roche's Tecentriq is listed as active but not recruiting - these were both to be funded by Imugene.
Her-Vaxx completed phase 2 with favourable results over SOC and is an alternative for Herceptin when it isn't available due to a patients toxicity or the availability due to cost. It doesn't appear to be best in class so now we wait for further developments, but as phase 3 are extremely expensive, I don't expect to hear any further updates of trials. It doesn't mean it's a failure, it has been proven to work.
So whilst shareholder were screaming about our acquisitions and how IMU should focus on their one drug, this just proves it pays to be more than a 1 trick pony.
Or I'm completely wrong and the company is as others have put it "a lifestyle company" for the BOD to live a comfy life until retirement.